Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis

@article{Moujalled2016AdvancesIT,
  title={Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis},
  author={Diane Moujalled and Anthony R White},
  journal={CNS Drugs},
  year={2016},
  volume={30},
  pages={227-243}
}
AbstractAmyotrophic lateral sclerosis (ALS) is a progressive adult-onset, neurodegenerative disease characterized by the degeneration of upper and lower motor neurons. Over recent years, numerous genes ha ve been identified that promote disease pathology, including SOD1, TARDBP, and the expanded hexanucleotide repeat (GGGGCC) within C9ORF72. However, despite these major advances in identifying genes contributing to ALS pathogenesis, there remains only one currently approved therapeutic: the… Expand
From animal models to human disease: a genetic approach for personalized medicine in ALS
TLDR
Subgroups of specific ALS-linked gene mutations are used to go through existing animal models and to provide a comprehensive profile of the differences and similarities between animal models of disease and human disease. Expand
Amyotrophic Lateral Sclerosis: Current Therapeutic Perspectives
TLDR
This chapter focuses on studies of various small pharmacological compounds targeting the proposed pathogenic mechanisms of ALS and discusses their impact on disease progression, and summarizes the progress in the non-pharmacological therapy trials in ALS. Expand
Harnessing the Potential of Human Pluripotent Stem Cell-Derived Motor Neurons for Drug Discovery in Amyotrophic Lateral Sclerosis: From the Clinic to the Laboratory and Back to the Patient
Amyotrophic Lateral Sclerosis (ALS) is a motor neurodegenerative disorder whose cellular hallmarks are the progressive death of motor neurons (MNs) located in the anterior horn of the spinal cord,Expand
Amyotrophic Lateral Sclerosis Modifiers in Drosophila Reveal the Phospholipase D Pathway as a Potential Therapeutic Target
TLDR
Two independent genome-wide screens for modifiers of degenerative phenotypes associated with the expression of transgenic constructs carrying familial ALS-causing alleles of FUS (hFUSR521C) and TDP-43 (hTDP- 43M337V) uncover a complex array of genes affecting either or both of the two strains. Expand
Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD
TLDR
How recent genetic studies have bridged the mechanistic understanding of these two related diseases is surveyed and how the genetics behind ALS and FTLD point to complex disorders, implicating non-neuronal cell types in disease pathophysiology is surveyed. Expand
Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis
TLDR
A trial of a K+ channel activator (retigabine) is underway, while edaravone is currently being considered for licensing by drug approval agencies based on a hypothesis that the elimination of free radicals may lead to protection of motor neurones. Expand
Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis
TLDR
These findings implicate immunosenescence and metabolism as novel targets for biomarkers and therapeutic discovery and suggest immunomodulation as an early intervention. Expand
Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis
TLDR
A concise discussion of recent advances in nanotechnology-based strategies in relation to combating specific pathophysiology relevant to ALS disease progression is provided and the future scope of using nanotechnology to develop innovative treatments for ALS patients is investigated. Expand
Systems Biology of RNA-Binding Proteins in Amyotrophic Lateral Sclerosis
TLDR
This chapter begins by summarizing the ALS and involvement of RBPs, and provides a comprehensive overview of applications of systems biology to study ALS, imagining that the integration of highly efficient computational tools with multiple omic analyses will help in the discovery of new therapeutic interventions in ALS. Expand
[Dimebon delays the onset of symptoms of FUS-proteinopathy in transgenic mice].
TLDR
Dimebon leads to an increase in the duration of presymptomatic stage and delays the manifestation of clinical symptoms of the neurodegenerative process in the experimental group and in the control group. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 137 REFERENCES
Mechanisms, models and biomarkers in amyotrophic lateral sclerosis
TLDR
Emerging proteomic markers of neuronal loss and glial activity in cerebrospinal fluid, a cortical signature derived from advanced structural and functional MRI, and the development of more sensitive measurements of lower motor neuron physiology are leading a new phase of biomarker-driven therapeutic discovery. Expand
Rodent Models of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophyExpand
SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments
TLDR
The SOD1 and TDP-43 animal models created to date are summarised, report on recent findings supporting the potential mechanisms of ALS pathogenesis, and correlate this understanding with current developments in the clinic. Expand
A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis
TLDR
The slowly progressive pathology observed in this mouse strain could provide a more appropriate model for studying early-stage pathological processes in ALS and aid the development of therapies forEarly-stage treatments. Expand
The past, present and future of stem cell clinical trials for ALS
TLDR
A critical review of current clinical trials using either mesenchymal or neural stem cells to treat ALS patients is provided and mechanisms of action, validity of conclusions and rationale for advancing stem cell treatment strategies for this devastating disorder are evaluated. Expand
Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis
TLDR
Results indicate that minocycline, which is clinically well tolerated, may represent a novel and effective drug for treatment of ALS. Expand
The non-cell-autonomous component of ALS: new in vitro models and future challenges.
  • L. Ferraiuolo
  • Medicine, Biology
  • Biochemical Society transactions
  • 2014
TLDR
The advent of induced pluripotent stem cell (iPSC) technology and the newly developed induced neural progenitor cells (iNPCs) have created unprecedented exciting opportunities to unravel the mechanisms involved in neurodegeneration and initiate high-throughput drug screenings. Expand
C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits
TLDR
A mouse model that mimics both neuropathological and clinical phenotypes of c9FTD/ALS is described, including hyperactivity, anxiety, antisocial behavior, and motor deficits. Expand
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis
TLDR
Ongoing research on the cellular pathways highlighted in this Review is predicted to open the door to new therapeutic interventions to slow disease progression in ALS. Expand
Excitotoxicity and Amyotrophic Lateral Sclerosis
TLDR
The intrinsic properties of motor neurons that render these cells particularly vulnerable to excitotoxicity and could explain the selective vulnerability ofMotor neurons in ALS are summarized to help to develop new and better therapeutic strategies that could protect motor neurons from excitOToxicity. Expand
...
1
2
3
4
5
...